Pai et al. found that the proportion of high ASPM-expressing cells in tumors was inversely proportional to the relapse-free survival rate of PCCA patients, and ASPM promoted the occurrence and progression of prostate cancer by enhancing Wnt-DVL-3 -β-catenin signaling [31]. This evidence concerns the gene DVL3 and prostate cancer.